Navigation Links
Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company
Date:11/25/2008

MISSISSAUGA, ON, Nov. 25 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin, today announced that fqubed, Inc., its San Diego-based research and development subsidiary, has signed a research and development collaboration agreement with a Fortune Global 500 company that develops and markets skin care products. Financial details of the agreement were not disclosed.

"The fqubed technologies have valuable applications beyond our primary focus on pharmaceutical products delivered to and through the skin," said Dan Chicoine, Nuvo's Chairman. "Collaboration agreements such as this allow us to leverage the power of our transdermal screening and high throughput formulation development platforms in complementary areas, and to improve our research capabilities so that we can more effectively develop our own topical drug pipeline."

Under the collaboration, fqubed will expand the scope of its TEMPEST(TM) high throughput experimentation (HTE) platform to evaluate potential formulations for its partner's product portfolio. TEMPEST(TM) is currently used to screen the impact that formulation variations have on the penetration of a drug molecule through skin. TEMPEST(TM) offers testing throughput significantly higher than conventional equipment thereby increasing the likelihood of new discoveries.

"Collaborations with leading third parties validate fqubed's HTE technology leadership position," added John M. Newsam, fqubed's President and Managing Director. "They also allow us to broaden and strengthen our proprietary HTE platforms with input from groups that have extensive and complementary experience with skin-applied products."

Nuvo acquired fqubed in 2005 to increase its ability to develop novel drug products for delivery to or through the skin. The Nuvo subsidiary has discovered molecular penetration enhancer (MPE(TM)) systems suitable for enhancing drug delivery and is advancing a portfolio of prospective new topical pain products.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development center in San Diego, California. For more information, please visit www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2007. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UCSD researchers identify potential new drug target for chronic leukemia
2. USC researchers identify novel approach for suppressing prostate cancer development
3. Children's National Dedicates New Research Facility
4. Researchers identify new leprosy bacterium
5. CVS/pharmacy Raising Funds for the St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign to Support Expanded Rehabilitation Services Center
6. VivoMetrics LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project
7. Marlo Thomas and St. Jude Childrens Research Hospital(R) Kick Off The 5th Anniversary of the Thanks and Giving(R) Campaign Asking America to Support St. Jude While Shopping this Holiday Season
8. Collexis Launches Innovative Reviewer Finder to Enhance the $30 Billion Health Research Grant Industry
9. Smoking, teens and their parents: New research
10. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
11. Researchers discover strategy for predicting the immunity of vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology: